

FORM PTO-1440	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1810R1	Serial No. 10/044,896
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Chuntharapai et al.	
		Filing Date 09 Jan 2002	Group 1644

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>JF</i>	1	4,885,166	05.12.89	Meyer et al.			
<i>JF</i>	2	4,902,618	20.02.90	Berg			
<i>JF</i>	3	6,180,370	30.01.01	Queen et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>YPL</i>	4	WO 96/34096	31.10.96	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

<i>YPL</i>	5	Anonymous, "Human Interferon Alpha Subtypes, URL: http://www.researchd.com/cytokines/ifnasubt.htm " Diagnostic Research, Inc. (retrieved on Nov 25, 2002)
	6	Jones et al., "Endocrine-Mediated Mechanisms of Fatigue During Treatment with Interferon-Alpha." <i>Seminars in Oncology</i> (Suppl. 1, ABSTRACT ONLY) 25(1):54-63 (Feb 1998)
	7	Little et al., "Of Mice and Men: Hybridoma and Recombinant Antibodies." <i>Immunology Today</i> 21(8):364-370 (Aug 2000)
<i>YPL</i>	8	Okanoue Takeshi et al., "Side Effects of High-Dose Interferon Therapy for Chronic Hepatitis C." <i>J. Hepatology</i> (ABSTRACT ONLY) 25(3):283-291 (1996)
<i>YPL</i>	9	Seifarth et al., "Augmented Immune Response to Islet Cell Antigens and Development of Diabetes Mellitus Under Treatment with Interferon-Alpha in Chronic Hepatitis C." <i>Zeitschrift Fuer Gastroenterologie</i> (ABSTRACT ONLY) 37(3):235-239 (Mar 1999)

RECEIVED


JAN 17 2003

TECH CENTER 1600/2900

Examiner	Date Considered
<i>YPL</i>	1/16/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.074A	APPLICATION NO. 10/044,896
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Chuntarapai et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE January 9, 2002	GROUP Unknown



U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
YK	1. 4,902,818	2/20/1990	Berg	435	172.2	

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
YK	2. EP 0139 676 B1	08.16.84	EP			
YK	3. GB 1 160 544 A	12.24.85	UK			
YK	4. GB 2 195 342 A	4.7.88	UK			
YK	5. WO 84/03105	8.16/84	PCT			
YK	6. WO 97/41229	11.6.98	PCT			
YK	7. WO 99/84481	12.16.99	PCT			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
YK	8. Adolf et al., "Production of Monoclonal Antibodies to human IFN- α and Their Use For Analysis of the Antigenic Composition of Various Natural Interferon" <i>Journal of Cellular Physiology Supplement</i> 2:61-68 (1982)
YK	9. Aguet et al., "A crystalline synthetic peptide representing the epitope of a monoclonal antibody raised against synthetic interferon- α 1 fragment 111-116" <i>Eur. J. Biochem.</i> 146:689-691 (1985)
YK	10. Alexenko et al. "The Antiproliferative and Antiviral Activities of IFN- α Variants in Human Cells" <i>Journal of Interferon and Cytokine Research</i> 17:767-779 (1997)
YK	11. Alken and Braun, "Epitope mapping of human recombinant interferon alpha molecules by monoclonal antibodies" <i>Ciba Found Symp</i> (Netherlands) 119:264-278 (1988)
YK	12. Andersson et al., "Application of Four Anti-Human Interferon- α Monoclonal Antibodies for Immunoassay and Comparative Analysis of Natural Interferon Mixtures" <i>Journal of Interferon Research</i> 11:53-60 (1991)
YK	13. Ansell, Philip R.J. "Hybridoma technology: a view from the patent arena" <i>Immunology Today</i> 21(8):357-358 (August 2000)
YK	14. Bach, Jean Francois, "Insulin -Dependent Diabetes Mellitus as an Autoimmune Disease" <i>Endocrine Reviews</i> 15(4):518-542 (1994)
YK	15. Baldeon et al., "interferon- α and interferon- γ differentially affect pancreatic β -cell phenotype and function" <i>American Physiological Society</i> C25-C32 (199)
YK	16. Batteux et al., "FCyRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus" <i>Eur. Cytokine Netw.</i> 10(4):505-513 (December 1999)


EXAMINER	YK	DATE CONSIDERED	1/13/05
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.074A	APPLICATION NO. 10/044,896
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Chuntarapai et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE January 9, 2002	GROUP Unknown

17.	Beilharz, Manfred W. Therapeutic potential for orally administered type 1 interferons" <i>PSIT</i> 3(6):183-197 (June 2000)
18.	Berg, Kurt, "Identification, Production, and Characterization of Murine Monoclonal Antibody (LO-22) Recognizing 12 Native Species of Human Alpha Interferon" <i>Journal of Interferon Research</i> 4:481-491 (1984)
19.	Bogdan, Christian "The function of type I Interferons in antimicrobial immunity" <i>Current Opinion in Immunology</i> 12:419-424 (2000)
20.	Borrebaeck, Carl A.K. "Antibodies in diagnostics-from immunoassays to protein chips" <i>Immunology Today</i> 21(8):379-357 (August 2000)
21.	Brod et al. "Ingested Interferon α suppresses Type I diabetes in non-obese diabetic mice" <i>Diabetologia</i> 41:1227-1232 (1998)
22.	Brod, Staley A. "Autoimmunity Is a Type I Interferon-Deficiency Syndrome Corrected by Ingested Type I IFN via the GALT System" <i>Journal of Interferon and Cytokine Research</i> 10:841-852 (1999)
23.	Campbell et al., "Essential Role of Interferon- γ and Interleukin-6 in Autoimmune Insulin-dependent Diabetes in NOD/Wehi Mice" <i>J. Clin. Invest.</i> 87:739- (February 1991)
24.	Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy" <i>Proc. Natl. Acad. Sci. USA</i> 89:4285-4289 (May 1992)
25.	Castano and Eisenbarth, "Type-I Diabetes: A chronic Autoimmune Disease of Human, Mouse, and Rat" <i>Annu. Rev. Immunol.</i> 8:647-679 (1990)
26.	Chakrabarti et al. "Control of Islet Intercellular Adhesion Molecule-1 Expression by Interferon- α and Hypoxia" <i>Diabetes</i> 45:1336-1343 (October 1996)
27.	Chakrabarti et al., "IFN- α Induces Autoimmune T Cells Through the Induction of Intracellular Adhesion Molecule-1 and B7.2" <i>Journal of Immunology</i> 0022-1767:522-528 (1996)
28.	Chehadeh et al., "Increased Level of Interferon- α in Blood of Patients with Insulin-Dependent Diabetes Mellitus: Relationship with Coxsackievirus B Infection" <i>Journal of Infectious Diseases</i> 181:1929-1939 (2000)
29.	Clark, Mark :Antibody Humanization: a case of the 'Emperor's new clothes?" <i>Immunology Today</i> 21(8):397-401 (August 2000)
30.	Clothia et al., "Conformations of immunoglobulin hypervariable regions", <i>Nature</i> 342:877-883 (December 1989)
31.	Dall'Acqua and Carter "Antibody engineering" <i>Current Opinion in Structural Biology</i> 8:443-450 (1998)
32.	Eaton et al., "Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule" <i>Biochemistry</i> 25(26):84 8347 9December 1986)
33.	Eigenbrot et al., "X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of Key Role of VH Residues 50 to 65" <i>Proteins: Structure, Function, and Genetics</i> 18:49-62 (1994)
34.	Exley et al., "A Comparison of the Neutralizing Properties of Monoclonal and Polyclonal Antibodies to Human Interferon Alpha" <i>J. Gen. Virol.</i> 65:2277-2 (1984)
35.	Fabris et al., "Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis" <i>Journal of Hepatology</i> 28:514-517(1998)
36.	Foulis et al., "Immunoreactive α -Interferon in Insulin-Secreting β Cells in TYPE 1 Diabetes Mellitus" <i>The Lancet</i> 1423-1427 (December 19, 1987)
37.	Garcia-Porrua et al., "Simultaneous development of SLE-like syndrome and auto-immune thyroids following α -interferon treatment" Letters to Editor 107 108
38.	Glennie and Johnson "Clinical trials of antibody therapy" <i>Immunology Today</i> 21(8):403-410 (August 2000)
39.	Gorman et al., "transient Production of Protein Using an Adenovirus Transformed Cell Line" (2) (November 1, 1990)
40.	Gresser, Ion, "Wherefore interferon?", <i>Journal of Leukocyte Biology</i> 61:567-574 (May 1997)
41.	Heim, Markus H. 'The Jak-STAT Pathway: Cytokine Signalling from the Receptor to the Nucleus" <i>J. of Receptor & Signal Transduction Research</i> 19(104):75-120 (1999)
42.	Hoogenboom and Charnes "Natural and designed binding sites made by phage display technology" <i>Immunology Today</i> 21(8):371-378 (August 2000)
43.	Hooks et al., "Multiple Interferons in the Circulation of Patients with Systemic Lupus Erythematosus and Vasculitis" <i>Arthritis and Rheumatism</i> , 25(4):39 400 (April 1982)
44.	Horton et al., "Antitumor Effects of Interferon- ω : In Vivo Therapy of Human Tumor Xenografts in Nude Mice" <i>Cancer Research</i> 59:4064-4068 (August 1
45.	Horvath et al., "A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain" <i>Genes & Development</i> 9:98 994 (1995)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.074A	APPLICATION NO. 10/044,896
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Chuntarapai et al.	
(USE SEVERAL SHEETS IF NECESSARY)		SEARCHING DATE January 9, 2002	GROUP Unknown



46. Huang et al., 'Interferon Expression in the Pancreases of Patients With Type I Diabetes' Diabetes 44:658-664 June 1995

47. Huang et al., 'Islet Expression of Interferon- α Precedes Diabetes in Both the BB Rat and Streptozotocin-Treated Mice' Immunity 1:469-478 (September 1994)

48. Hudson, Peter J. 'Recombinant antibody constructs in cancer therapy' Current Opinion in Immunology 11:548-557 (1999)

49. John et al., 'Isolation and Characterization of a New Mutant Human Cell Line Unresponsive to Alpha and Beta Interferons' Molecular and Cellular Biology 11(8):4189-4195 (August 1991)

50. Kabat, et al. 'Sequences of Proteins of Immunological Interest' Fifth Edition U.S. Department of Health and Human Services Publication No. 91-3243 (1991)

51. Kanayama et al., 'Serum levels of interferon in patients with systemic lupus erythematosus' Clin. Exp. Immunol. 70:562-569 (1987)

52. Kandefer-Sztern and Lungren 'Three Separate Epitopes on Human IFN- α Variants Defined by Monoclonal Antibodies and Their Role in the Binding to Receptors' Archivum Immunologiae et Therapae Experimentalis 40:241-248 (1992)

53. Kay et al., 'The Beta Cell in Autoimmune Diabetes: Many Mechanisms and Pathways of Loss' TEM 11(1):11-15 (2000)

54. Kontsek et al., 'Antigenic Link Between Human Interferons- α and - β : The Common Epitope 1' Journal of Interferon Research 10:119-128 (1999)

55. Kudela et al., 'Conformational Changes in Ph2-Treated Human Interferon-Alpha 2 Detected with Monoclonal Antibodies' HYBRIDOMA 15(3):185-189 (November 1996)

56. Kunkel, Thomas A., 'Rapid and efficient site-specific mutagenesis without phenotype selection' Proc. Natl. Acad. Sci. USA 82:488-492 (January 1985)

57. Kurabayashi et al., 'Doxorubicin-Induced Id2A Gene Transcription Is Targeted at an Activation Transcription Factor/Cyclic AMP Response Element Motif through Novel Mechanisms Involving Protein Kinases Distinct from Protein Kinase C and Protein Kinase A' Molecular and Cellular Biology 14(11):6386-6397 (Nov. 1995)

58. Lacki et al., 'Cytokine concentration in serum of Lupus erythematosus patients: the effect on acute phase response' Journal of Medicine 28 Nos. 1 & 2, pp.99-107 (1997)

59. Lau et al., 'Interferon regulatory factor subcellular localization is determined by a bipartite nuclear localization signal in the DNA-binding domain and interaction with cytoplasmic retention factors' PNAS 97(13):7278-7283 (June 2000)

60. Laurent et al., 'Purification of the Major Species of Human Leucocyte Interferon With the Help of a Monoclonal Antibody' Dev. Biol. Stand. (Switzerland) 57:305-310 (1984)

61. Lefevre et al. 'Interferon-delta: The first member of a novel type I interferon family' Biochimie 80:779-788 (1998)

62. Little et al., 'Of mice and men: hybridoma and recombinant antibodies' Immunology Today 21(8):364-370 (August 2000)

63. Lydon et al., 'Immunochemical Mapping of α -2 Interferon' Biochemistry 24:4131-4141 (1985)

64. Mannel et al., 'A rat monoclonal antibody against mouse α and β interferon of all molecular weight species' Nature 296:664-665 (April 1982)

65. Matsumoto et al., 'Activation of the Transcription Factor ISGF3 by Interferon- γ ' Biol. Chem. 380:699-703 (June 1998)

66. McKendry et al., 'High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both α and γ interferons' Proc. Natl. Acad. Sci. USA 88:11455-11459 (December 1991)

67. Meager, Anthony 'Natural Autoantibodies to Interferons' Journal of Interferon and Cytokine Research 17 SUP 1:S51-S53 (1997)

68. Meager and Berg, 'Editope Localization of a Monoclonal Antibody, LO-22, With Broad Specificity for Interferon- α Subtypes' Journal of Interferon Research 6:729-736 (1988)

69. Milstein, Cesar 'With the benefit of hindsight' Immunology Today 21(8):359-364 (August 2000)

70. Noll et al., 'Production and characterization of four monoclonal antibodies specific for human interferon-alpha1 and alpha-2' Biomed. Biocim. Acta 48(1):165-176 (1989)

71. Novak et al., 'Preparation and Characterization of Hybridomas Producing Monoclonal Antibodies Against Human Alpha Interferon' Acta Virol. 30P228-2 (1986)

72. Osherson et al., 'Monoclonal Antibodies to a Recombinant Human Leukocyte Interferon (Rifn- α B)' Clinical Immunology and Immunopathology 30:188-192 (1984)

73. Presta et al., 'Humanization of an Antibody Directed Against IgE' The Journal of Immunology 151:2623-2632 (September 1, 1993)

EXAMINER	DATE CONSIDERED
1/18/05	
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.074A	APPLICATION NO. 10/044,896
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APR 09 2002 JC5 U.S. PATENT & TRADEMARK OFFICE	
(USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Chuntarapai et al.	
		FILING DATE January 9, 2002	GROUP Unknown

74.	Rabinovitch, Alex, "An Update on Cytokines in the Pathogenesis of Insulin-dependent Diabetes Mellitus" <i>Diabetes/Metabolism Reviews</i> 14:129-151 (1998)
75.	Reichert, Janice M. "New biopharmaceuticals in the USA: Trends in development and marketing approvals 1995-1999" <i>TIBTECH</i> 18:364-369 (September 2000)
76.	Rhodes et al., "Effect of Human lymphoblastoid interferon on insulin synthesis and secretion in isolated human pancreatic islets" <i>Diabetologia</i> 27:601-60 (1984)
77.	Robak et al., "Association of Interferon γ , Tumor Necrosis Factor α and Interleukin 6 Serum Levels with Systemic Lupus Erythematosus Activity" <i>Archiv Immunologia et Therapii Experimentalis</i> 46:375-380 (1998)
78.	Roberts et al., "The Evolution of the Type I Interferons" <i>Journal of Interferon and Cytokine Research</i> 18:805-816 (1998)
79.	Ronnblom et al., "Case Report. Possible Induction of systemic lupus erythematosus by interferon- α treatment in a patient with a malignant carcinoid tumour" <i>Journal of Internal Medicine</i> 227:207-210 (1990)
80.	Sattayasai et al., "Universal Antibodies to Human Interferon- α Subtypes-The Production of Antipeptide Antibodies to Conserved Regions of Interferon- α " <i>Journal of Interferon Research</i> 11:41-48 (1991)
81.	Shearer et al., "Monoclonal Antibodies that Distinguish Between Subspecies of Human Interferon- α and that Detect Interferon Oligomers" <i>The Journal of Immunology</i> 133(6):3098-3101 (December 1984)
82.	Shehaden and Lafferty, "The role of T-cells in the development of autoimmune diabetes" <i>Diabetes Reviews</i> 1(2):141-151 (1993)
83.	Shiozawa et al., "Interferon-Alpha in Lupus Psychosis" <i>Arthritis and Rheumatism</i> 35(4):417-422 (April 1992)
84.	Shou-Nee et al., "Serum interferon in systemic lupus erythematosus" <i>British Journal of Dermatology</i> 117:155-159 (1987)
85.	Sobel and Ahvazi, " α -Interferon Inhibits the Development of Diabetes in NOD Mice" <i>Diabetes</i> 47:1867-1872 (December 1998)
86.	Sobel et al. "Alpha Interferon Administration Paradoxically Inhibits the Development of Diabetes in BB Rats" <i>Life Sciences</i> 62(15):1293-1302 (1998)
87.	Somoza et al., "Pancreas in Recent Onset Insulin-Dependent Diabetes Mellitus" <i>The Journal of Immunology</i> 136:1-1377 (1994)
88.	Staehelin et al., "Production of hybridomas secreting monoclonal antibodies to the human leukocyte interferons" <i>Proc. Natl. Acad. Sci. USA</i> 78(3):1848-1852 (March 1981)
89.	Stewart et al. "Induction of Type I Diabetes by Interferon- α in Transgenic Mice" <i>Science</i> 260:1942-1946 (Jun 1993)
90.	Tanaka-Kataoka et al. "Oral Use of Interferon- α Delays the Onset of Insulin-Dependent Diabetes Mellitus in Nonobese Diabetes Mice" <i>Journal of Interferon and Cytokine Research</i> 19:877-879 (1999)
91.	Tramontano et al., "Framework Residue 71 is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the V κ Domains of Immunoglobulins" <i>J. Mol. Biol.</i> 215:175-182 (1990)
92.	Tsukui et al., "A monoclonal Antibody with Broad Reactivity to Human Interferon- α Subtypes Useful for Purification of Leukocyte-Derived Interferon" <i>Microbiol. Immunol.</i> 30(11):1129-1139 (1986)
93.	Viscomi et al., "Antigenic Characterization of Recombinant Lymphoblastoids and Leukocyte IFN- α by Monoclonal Antibodies" <i>Journal of Interferon and Cytokine Research</i> 19:3190-326 (1999)
94.	Waguri et al., "Occurrence of IDDM during interferon therapy for chronic viral hepatitis" <i>Diabetes Research and Clinical Practice</i> 23:33-38 (1994)
95.	Wathelet et al., "Virus Infection Induces the Assembly of Coordinately Activated Transcription Factors on the IFN- β Enhancer In Vivo" <i>Molecular Cell</i> 1:518 (March 1998)
96.	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <i>The Journal of Immunology</i> 158:4988-4995 (1996)
97.	Wusow et al., "Presence of Interferon and anti-Interferon in patients with systemic lupus erythematosus" <i>Rheumatol. Int.</i> 8:225-230 (1988)
98.	Xiang et al., "Framework Residues 71 and 93 of the Chimeric B72.3 Antibody are Major Determinants of the Conformation of Heavy-chain Hypervariable Loops" <i>J. Mol. Biol.</i> 253:385-390 (1995)
99.	Ytterberg and Schnitzer, "Serum Interferon Levels in Patients with Systemic Lupus Erythematosus" <i>Arthritis and Rheumatism</i> , 25(4):401-406 (April 1982)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	